[CAS NO. 1018448-65-1] Trastuzumab emtansine
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1018448-65-1]
Store
Catalog
HY-P9921
Brand
MCE
CAS
1018448-65-1
DESCRIPTION [1018448-65-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | Unspecified |
| SMILES | [Trastuzumab emtansine] |
For research use only. We do not sell to patients.
Summary
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate ( ADC ) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer [1] [2] .
In Vitro
Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | CB-17/SCID mice (6 weeks) were injected with OVA10 cells [2] |
| Dosage: | 15 mg/kg |
| Administration: | I.v. three to five times weekly for 3 weeks |
| Result: | Showed remarkable inhibition of tumor growth in mice and was well tolerated. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05408845 | NRG Oncology|National Cancer Institute (NCI) |
Metastatic Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage III Major Salivary Gland Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Unresectable Salivary Gland Carcinoma
|
November 10, 2022 | Phase 2 |
| NCT00679341 | Hoffmann-La Roche |
Breast Cancer
|
September 2008 | Phase 2 |
| NCT04680442 | Population Health Research Institute |
Breast Cancer|Heart Failure
|
July 1, 2021 | Phase 2 |
| NCT02236000 | NSABP Foundation Inc|Puma Biotechnology, Inc. |
Breast Cancer
|
August 2014 | Phase 1|Phase 2 |
| NCT04620187 | Dana-Farber Cancer Institute|Genentech, Inc. |
Salivary Gland Cancer|HER2 Gene Mutation
|
December 24, 2020 | Phase 2 |
| NCT04486352 | Alliance Foundation Trials, LLC.|Genentech, Inc.|Foundation Medicine|Pfizer |
Endometrial Cancer
|
October 20, 2021 | Phase 1|Phase 2 |
| NCT05288777 | University of Virginia |
Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III
|
May 2022 | Phase 2|Phase 3 |
| NCT03709082 | University of Kansas Medical Center|Pfizer |
HER2-positive Breast Cancer|Breast Cancer Metastatic
|
October 15, 2018 | Phase 1|Phase 2 |
| NCT04341181 | Ulrik Lassen|Roche Pharma AG|Pfizer|GlaxoSmithKline|Rigshospitalet, Denmark |
Cancer|Tumors|Neoplasms|Neoplasia
|
August 24, 2020 | Phase 2 |
| NCT01816035 | University of Washington|National Cancer Institute (NCI) |
HER2+Neu Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
June 2014 | Phase 1 |
| NCT01565200 | Jules Bordet Institute|Roche Pharma AG |
HER-2 Positive Breast Cancer
|
May 2012 | Phase 2 |
| NCT02038010 | Northwestern University|Novartis|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
May 21, 2014 | Phase 1 |
| NCT01042379 | QuantumLeap Healthcare Collaborative |
Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
|
March 1, 2010 | Phase 2 |
| NCT01904903 | Medstar Health Research Institute|Genentech, Inc. |
HER2 Positive Breast Cancer|Left Ventricular Function Systolic Dysfunction
|
October 2013 | Phase 2 |
| NCT04296942 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Triple Negative Breast Cancer|HER2&addition; Breast Cancer|Hormone Receptor Negative Breast Cancer|Metastatic Breast Cancer
|
May 4, 2021 | Phase 1 |
| NCT04419181 | University of Rochester |
HER2-positive Breast Cancer
|
June 1, 2023 | Phase 2 |
| NCT01835236 | Swiss Group for Clinical Cancer Research |
Metastatic Breast Cancer
|
March 3, 2013 | Phase 2 |
| NCT04632992 | Genentech, Inc. |
Advanced Unresectable or Metastatic Solid Malignancy
|
January 13, 2021 | Phase 2 |
| NCT02658084 | University of Miami|Genentech, Inc. |
Breast Cancer|Metastatic Breast Cancer
|
April 12, 2017 | Phase 1|Phase 2 |
| NCT03190967 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Brain Metastasis|Brain Cancer
|
April 18, 2018 | Phase 1|Phase 2 |
| NCT03032107 | Dana-Farber Cancer Institute|Merck Sharp & Dohme LLC |
Breast Cancer
|
February 17, 2017 | Phase 1 |
| NCT04769050 | Fudan University |
Breast Cancer
|
February 18, 2021 | |
| NCT02465060 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer
|
August 12, 2015 | Phase 2 |
| NCT01120184 | Hoffmann-La Roche|Genentech, Inc. |
Breast Cancer
|
July 31, 2010 | Phase 3 |
| NCT04740918 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
June 7, 2021 | Phase 3 |
| NCT03530696 | University of Arizona|Pfizer |
HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma
|
December 6, 2018 | Phase 2 |
| NCT05593094 | Suzhou Zanrong Pharma Limited |
Advanced Solid Tumors|HER2-positive Breast Cancer
|
October 15, 2020 | Phase 1 |
| NCT00509769 | Genentech, Inc. |
Metastatic Breast Cancer
|
July 2007 | Phase 2 |
| NCT04873362 | Hoffmann-La Roche |
Breast Cancer
|
May 4, 2021 | Phase 3 |
| NCT01745965 | West German Study Group|Roche Pharma AG |
Breast Cancer
|
November 2012 | Phase 2 |
| NCT02226276 | City of Hope Medical Center|National Cancer Institute (NCI) |
Bone Metastases|HER2-positive Breast Cancer|Liver Metastases|Lung Metastases|Recurrent Breast Cancer|Soft Tissue Metastases|Stage IV Breast Cancer
|
January 7, 2015 | Not Applicable |
| NCT01419197 | Hoffmann-La Roche |
Breast Cancer
|
September 2011 | Phase 3 |
| NCT03429101 | Spectrum Pharmaceuticals, Inc |
Breast Cancer
|
July 13, 2018 | Phase 1 |
| NCT03418558 | Fondazione del Piemonte per l´Oncologia |
Metastatic Colorectal Cancer
|
July 8, 2015 | Phase 2 |
| NCT04733118 | MedSIR|Hoffmann-La Roche |
Early Breast Cancer
|
August 5, 2021 | Phase 2 |
| NCT01966471 | Hoffmann-La Roche |
Breast Cancer
|
January 31, 2014 | Phase 3 |
| NCT02605915 | Hoffmann-La Roche |
HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer
|
December 31, 2015 | Phase 1 |
| NCT01702571 | Hoffmann-La Roche |
Breast Cancer
|
November 27, 2012 | Phase 3 |
| NCT04439110 | National Cancer Institute (NCI) |
Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma
|
August 12, 2015 | Phase 2 |
| NCT01702558 | Hoffmann-La Roche |
Breast Cancer|Gastric Cancer
|
December 3, 2012 | Phase 2 |
| NCT05525858 | Seoul National University Bundang Hospital|Korean Cancer Study Group|Roche Pharma AG |
Solid Tumor|Advanced Solid Tumor|Metastatic Cancer
|
September 28, 2022 | |
| NCT04398914 | Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer Invasive
|
May 30, 2020 | Phase 2 |
| NCT04351230 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
|
November 11, 2020 | Phase 2 |
| NCT03364348 | George W. Sledge Jr.|National Cancer Institute (NCI)|Stanford University |
HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
October 30, 2017 | Phase 1 |
| NCT01853748 | Dana-Farber Cancer Institute |
Breast Cancer
|
May 2013 | Phase 2 |
| NCT03784599 | The Netherlands Cancer Institute|AstraZeneca|Roche Pharma AG |
Carcinoma, Non-Small-Cell Lung
|
December 18, 2018 | Phase 2 |
| NCT02318901 | Western Regional Medical Center |
Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer
|
October 2014 | Phase 1|Phase 2 |
| NCT00934856 | Hoffmann-La Roche |
Breast Cancer
|
July 2009 | Phase 1|Phase 2 |
| NCT05560308 | Tianjin Medical University Cancer Institute and Hospital |
HER2&addition; Advanced Breast Cancer Patients Progressing on TKI Therapy
|
September 30, 2022 | Not Applicable |
| NCT01196052 | Hoffmann-La Roche |
Breast Cancer
|
October 2010 | Phase 2 |
| NCT03153163 | Hoffmann-La Roche |
Breast Neoplasms
|
June 20, 2017 | Phase 1 |
| NCT02073916 | Jenny C. Chang, MD|The Methodist Hospital Research Institute |
Metastatic Breast Cancer
|
October 2013 | Phase 1 |
| NCT02657343 | Dana-Farber Cancer Institute|Novartis |
Breast Cancer
|
March 9, 2016 | Phase 1|Phase 2 |
| NCT00829166 | Hoffmann-La Roche |
Breast Cancer
|
February 2009 | Phase 3 |
| NCT02390427 | Otto Metzger|Genentech, Inc.|Dana-Farber Cancer Institute |
Metastatic Breast Cancer|Recurrent Breast Cancer
|
April 20, 2015 | Phase 1 |
| NCT01494662 | Dana-Farber Cancer Institute|Translational Breast Cancer Research Consortium|Puma Biotechnology, Inc. |
Breast Cancer
|
February 2012 | Phase 2 |
| NCT04457596 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Seagen Inc. |
Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Synchronous Bilateral Breast Carcinoma
|
January 6, 2021 | Phase 3 |
| NCT04266249 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8
|
February 11, 2020 | Phase 2 |
| NCT00875979 | Hoffmann-La Roche|Roche Pharma AG |
Metastatic Breast Cancer
|
May 2009 | Phase 1|Phase 2 |
| NCT01976169 | University of Texas Southwestern Medical Center|Pfizer|University of Pennsylvania |
Advanced Breast Cancer
|
January 24, 2014 | Phase 1 |
| NCT04675827 | Jules Bordet Institute|Breast International Group|Hoffmann-La Roche|International Drug Development Institute|Institut Curie |
HER2-positive Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|Node-negative Breast Cancer
|
January 17, 2022 | Phase 2 |
| NCT05429684 | First Affiliated Hospital Xi´an Jiaotong University |
HER2&addition; Breast Cancer
|
January 1, 2021 | Phase 3 |
| NCT01772472 | Hoffmann-La Roche|NSABP Foundation Inc|German Breast Group |
Breast Cancer
|
April 3, 2013 | Phase 3 |
| NCT04197687 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
February 20, 2020 | Phase 2 |
| NCT04042051 | Cancer Trials Ireland |
HER2-positive Breast Cancer|Metastatic Breast Cancer|Locally Advanced Breast Cancer|Unresectable Breast Cancer
|
November 12, 2019 | Phase 1 |
| NCT04931342 | Hoffmann-La Roche|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Ovarian Cancer
|
October 7, 2021 | Phase 2 |
| NCT02131064 | Hoffmann-La Roche |
Breast Neoplasms
|
June 25, 2014 | Phase 3 |
| NCT03894007 | Renske Altena|Karolinska University Hospital |
Early-stage Breast Cancer|HER2-positive Breast Cancer
|
May 23, 2019 | Phase 2 |
| NCT03878524 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic+Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic+Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma
|
April 1, 2020 | Phase 1 |
| NCT02924883 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
September 26, 2016 | Phase 2 |
| NCT00679211 | Genentech, Inc. |
Metastatic Breast Cancer
|
August 2008 | Phase 2 |
| NCT02999672 | Hoffmann-La Roche |
Bladder Cancer|Pancreas Cancer|Cholangiocellular Carcinoma
|
December 23, 2016 | Phase 2 |
| NCT02658734 | Hoffmann-La Roche |
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
|
November 1, 2016 | Phase 4 |
| NCT04509596 | Dizal Pharmaceuticals |
Breast Cancer Metastatic
|
September 21, 2020 | Phase 1 |
| NCT05238831 | OHSU Knight Cancer Institute|Oregon Health and Science University|Genentech, Inc. |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Ovarian Carcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Refractory Breast Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Ovarian Carcinoma|Stage III Ovarian Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Unresectable Malignant Solid Neoplasm|Unresectable Ovarian Carcinoma
|
December 1, 2022 | Phase 2 |
| NCT03587740 | Dana-Farber Cancer Institute|Susan G. Komen Breast Cancer Foundation|Gateway for Cancer Research |
Breast Cancer
|
August 22, 2018 | Phase 2 |
| NCT00833963 | Genentech, Inc. |
Breast Cancer|Pregnancy
|
January 14, 2009 | |
| NCT04589845 | Hoffmann-La Roche |
Solid Tumors
|
January 18, 2021 | Phase 2 |
| NCT01983501 | Seagen Inc. |
HER2 Positive Breast Cancers
|
February 28, 2014 | Phase 1 |
| NCT00951665 | Genentech, Inc. |
Metastatic Breast Cancer
|
August 2009 | Phase 1|Phase 2 |
| NCT02725541 | Jenny C. Chang, MD|Genentech, Inc.|The Methodist Hospital Research Institute |
Breast Cancer
|
March 2016 | Phase 2 |
| NCT01513083 | Hoffmann-La Roche |
Breast Cancer
|
February 2012 | Phase 1 |
| NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical |
Breast Cancer
|
January 11, 2019 | Phase 3 |
| NCT02073487 | The Methodist Hospital Research Institute|Celgene Corporation|Novartis |
Breast Cancer
|
February 2014 | Phase 2 |
| NCT01641939 | Hoffmann-La Roche |
Gastric Cancer
|
September 3, 2012 | Phase 2|Phase 3 |
| NCT03084939 | Hoffmann-La Roche |
Breast Cancer
|
April 24, 2017 | Phase 3 |
| NCT05415215 | Hoffmann-La Roche |
Early Breast Cancer|Locally Advanced Breast Cancer|Inflammatory Breast Cancer
|
July 5, 2022 | Phase 3 |
| NCT02144012 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
June 2014 | Phase 3 |
| NCT04622319 | Daiichi Sankyo, Inc.|AstraZeneca|NSABP Foundation Inc|German Breast Group|Spanish Breast Cancer Research Group (SOLTI) |
HER2-Positive Primary Breast Cancer|Residual Invasive Breast Cancer
|
December 4, 2020 | Phase 3 |
| NCT02675829 | Memorial Sloan Kettering Cancer Center|Genentech, Inc. |
Solid Tumor Cancers|Lung Cancer|Bladder Cancer|Urinary Tract Cancers
|
February 2016 | Phase 2 |
| NCT00781612 | Genentech, Inc.|Hoffmann-La Roche |
Neoplasm Metastasis
|
October 16, 2008 | Phase 2 |
| NCT00943670 | Genentech, Inc. |
Metastatic Breast Cancer
|
July 2009 | Phase 2 |
| NCT05323955 | Carey Anders, M.D.|Seagen Inc.|Duke University |
Brain Metastases|Human Epidermal Growth Factor 2 Positive Carcinoma of Breast|Advanced Breast Cancer
|
September 1, 2022 | Phase 2 |
| NCT04298918 | Hoffmann-La Roche |
Breast Cancer
|
September 23, 2020 | Phase 1|Phase 2 |
| NCT04591431 | Fondazione per la Medicina Personalizzata |
Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer
|
October 7, 2020 | Phase 2 |
| NCT02326974 | Dana-Farber Cancer Institute|Genentech, Inc. |
HER-2 Positive Breast Cancer|Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
|
January 2015 | Phase 2 |
| NCT03975647 | Seagen Inc. |
HER2-positive Breast Cancer
|
October 2, 2019 | Phase 3 |
| NCT03529110 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
August 9, 2018 | Phase 3 |
| NCT02289833 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
December 15, 2014 | Phase 2 |
| NCT02314481 | University College, London|Hoffmann-La Roche |
Non-small Cell Lung Cancer
|
May 12, 2017 | Phase 2 |
| NCT04158947 | xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University |
HER2-positive Breast Cancer|Brain Metastases
|
May 10, 2020 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Store at 4°C, do not freeze
References
- [1] Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.
- [2] Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.
Synonyms
Immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 γ1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer, tetraamide with N2′-[3-[[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]-N2′-deacetylmaytansine
PRO 132365
T-DM 1
Trastuzumab-MCC-DM 1
Trastuzumab emtansine
Kadcyla
Ado-trastuzumab emtansine
RG 3502
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.